

**The Australian Stock Exchange Limited
Companies Announcements Office
SYDNEY****25 August 2009****PCC® EFFECTIVE IN REDUCING ILLNESS IN ATHLETES IN CLINICAL TRIAL**

Probiomics Limited is pleased to advise of positive results from a recently completed clinical trial showing that its proprietary product, *Lactobacillus fermentum* PCC®, reduces illness in a group of well-trained male cyclists over a winter training period. This study supports the findings of previous studies that PCC® is able to provide a significant positive effect on the mucosal immune system in groups as diverse as elite athletes, infants and a vaccinated population.

The present study was conducted in collaboration with Christian Hansen A/S, Griffith University and the Australian Institute of Sport (AIS) in a group of well-trained male and female cyclists over an 11 week training period.

The double blind, placebo-controlled trial used the dosage found in Probiomics' commercial product, Progastrim1 (1 billion living bacteria per capsule). This dosage was effective at reducing the severity and illness load of chest infection and medication use associated with respiratory tract infections (colds and flus) in the male cyclists. Furthermore, the researchers found that consuming PCC® moderated the negative effects of exercise stress on the immune system in both male and female cyclists. Exercise stress on the immune system is known to increase susceptibility to illness in individuals undertaking prolonged intense exercise.

No adverse effects were reported during the study.

These findings confirm results of an earlier study using a higher dose, also conducted at the AIS in elite highly trained male distance runners and published in the British Journal of Sports Medicine in February 2008. This previous study reported a substantial reduction in the number of days and severity of respiratory illness in those athletes consuming PCC® at a daily dose of 12 billion living bacteria.

The findings of these studies support the statement that *PCC*[®] can be a useful nutritional adjunct which can reduce illness in individuals engaged in prolonged intense exercise or when the immune system is under physical stress. The data from these studies will be used to support the targeted marketing and sales of *PCC*[®] in a range of products as they are developed, and builds the case for *PCC*[®]'s unique probiotic properties in supporting a healthy immune system.

In Australia, Progastrim1 can be purchased directly from the offices of Probimoics Limited by phoning on 02 9844 5422.

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – *PCC*[®]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing *PCC*[®] to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary
Tel: 02 9844 5422
Email ashok.jairath@probiomics.com.au